The medicines regulator has already warned concerning the potential dangers of taking the drug.
In 2016, it mentioned infants uncovered to sodium valproate within the womb had a excessive danger of significant developmental problems (in as much as 30-40% of instances) and congenital malformations (in 10% of instances), exterior.
Neurodevelopmental problems are situations that have an effect on how the mind features.
They vary from minor limitations permitting these affected to reside pretty regular lives, to problems that require lifelong care.
In line with the MHRA these embrace mental problems, communication problems, autism, ADHD, particular studying problems, motor problems, tic problems and different neurodevelopmental problems.
An estimated 20,000 youngsters within the UK have had life-changing accidents from the medication.
In January, the MHRA mentioned men and women underneath the age of 55 mustn’t take sodium valproate until all different remedy choices had been rejected and its use had been signed off by two impartial specialists.
Nonetheless, 65,000 youngsters and adults underneath 55 nonetheless take sodium valproate.
Households within the UK and overseas say their considerations concerning the results of the drug on their youngsters have been dismissed for years earlier than the European Medicines Company issued warnings in 2018.
